GRAND PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.32 HKD | +1.41% |
|
+8.82% | +5.62% |
| Sales 2023 | 10.53B 1.35B 108B | Sales 2024 * | 12.06B 1.54B 123B | Capitalization | 15.13B 1.93B 155B |
|---|---|---|---|---|---|
| Net income 2023 | 1.88B 240M 19.23B | Net income 2024 * | 2.44B 312M 25.01B | EV / Sales 2023 | 1.37 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 1.25 x |
| P/E ratio 2023 |
7.63
x | P/E ratio 2024 * |
6.26
x | Employees | - |
| Yield 2023 |
6.36% | Yield 2024 * |
3.01% | Free-Float | 28.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Grand Pharmaceutical Group Limited
More press releases
| 1 day | +1.41% | ||
| 1 week | +8.82% | ||
| Current month | +5.11% | ||
| 1 month | +2.61% | ||
| 3 months | +24.14% | ||
| 6 months | +5.37% | ||
| Current year | +5.62% |
1 week
3.93
4.34
1 month
3.834.34
Current year
3.174.34
1 year
3.175.40
3 years
3.178.45
5 years
3.178.99
10 years
1.278.99
| Managers | Title | Age | Since |
|---|---|---|---|
Chao Zhou
CEO | Chief Executive Officer | 34 | 31/03/19 |
Tin Chung Foo
SEC | Corporate Secretary | 56 | 31/08/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tosi Wan So
BRD | Director/Board Member | 61 | 20/03/05 |
Ye Bi Hu
BRD | Director/Board Member | 60 | 30/12/18 |
Geng Pei
BRD | Director/Board Member | 64 | 11/05/11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.86% | 4 M€ | -27.92% | ||
| 0.01% | 117 M€ | +1.11% | - | |
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.32 | +1.41% | 5,759,000 |
| 25/04/24 | 4.26 | +5.19% | 5,492,500 |
| 24/04/24 | 4.05 | +1.50% | 1,701,500 |
| 23/04/24 | 3.99 | 0.00% | 1,097,000 |
| 22/04/24 | 3.99 | +0.50% | 4,152,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
Sector
Pharmaceuticals
Calendar
06/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.32
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.62% | 1.93B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 512 Stock
